PubMed

The polyamine transport system as a target for anticancer drug development.

Palmer AJ, Wallace HM.

Amino Acids. 2009 Dec 3. [Epub ahead of print]PMID: 19956998 [PubMed - as supplied by publisher]Related articles

Two-Year Body Composition Analyses of Long-Lived GHR Null Mice.

Berryman DE, List EO, Palmer AJ, Chung MY, Wright-Piekarski J, Lubbers E, O'Connor P, Okada S, Kopchick JJ.

J Gerontol A Biol Sci Med Sci. 2009 Nov 9. [Epub ahead of print]PMID: 19901018 [PubMed - as supplied by publisher]Related articles

A putrescine-anthracene conjugate: a paradigm for selective drug delivery.

Palmer AJ, Ghani RA, Kaur N, Phanstiel O, Wallace HM.

Biochem J. 2009 Dec 10;424(3):431-8.PMID: 19811451 [PubMed - in process]Related articles

A hexapole magnetic guide for neutral atomic beams.

Beardmore JP, Palmer AJ, Kuiper KC, Sang RT.

Rev Sci Instrum. 2009 Jul;80(7):073105.PMID: 19655941 [PubMed]Related articles

Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes.

List EO, Palmer AJ, Berryman DE, Bower B, Kelder B, Kopchick JJ.

Diabetologia. 2009 Aug;52(8):1647-55. Epub 2009 May 26.PMID: 19468705 [PubMed - indexed for MEDLINE]Related articles

Older people and their social spaces: a study of well-being and attachment to place in Aotearoa New Zealand.

Wiles JL, Allen RE, Palmer AJ, Hayman KJ, Keeling S, Kerse N.

Soc Sci Med. 2009 Feb;68(4):664-71. Epub 2008 Dec 26.PMID: 19110361 [PubMed - indexed for MEDLINE]Related articles

Age-related changes in body composition of bovine growth hormone transgenic mice.

Palmer AJ, Chung MY, List EO, Walker J, Okada S, Kopchick JJ, Berryman DE.

Endocrinology. 2009 Mar;150(3):1353-60. Epub 2008 Oct 23.PMID: 18948397 [PubMed - indexed for MEDLINE]Related articles

Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.

Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C; PROactive Study Group.

Value Health. 2009 Jan;12(1):1-9. Epub 2008 Jul 24.PMID: 18657104 [PubMed - in process]Related articles

Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.

Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K.

Adv Ther. 2008 Jun;25(6):567-84.PMID: 18568451 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.

Ray JA, Borker R, Barber B, Valentine WJ, Belozeroff V, Palmer AJ.

Value Health. 2008 Sep-Oct;11(5):800-8. Epub 2008 May 20.PMID: 18494747 [PubMed - indexed for MEDLINE]Related articles

Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.

Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ.

Int J Clin Pract. 2008 Jun;62(6):869-76.PMID: 18479280 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.

Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O.

Diabetes Care. 2008 Aug;31(8):1510-5. Epub 2008 Apr 28.PMID: 18443195 [PubMed - indexed for MEDLINE]Related articlesFree article

[Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark]

Palmer AJ, Lammert M, Hermansen K.

Ugeskr Laeger. 2008 Apr 7;170(15):1250-4. Danish. PMID: 18433583 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.

Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, Valentine WJ, Palmer AJ.

Value Health. 2008 Mar;11 Suppl 1:S43-51.PMID: 18387067 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.

Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.

Curr Med Res Opin. 2008 May;24(5):1417-28. Epub 2008 Apr 8.PMID: 18400145 [PubMed - indexed for MEDLINE]Related articles

A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.

Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA.

Nephrol Dial Transplant. 2008 Apr;23(4):1216-23.PMID: 18359872 [PubMed - indexed for MEDLINE]Related articles

Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.

Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ.

Value Health. 2008 Jan-Feb;11(1):22-33.PMID: 18237357 [PubMed - indexed for MEDLINE]Related articles

Discovery and uses of pegvisomant: a growth hormone antagonist.

Berryman DE, Palmer AJ, Gosney ES, Swaminathan S, DeSantis D, Kopchick JJ.

Endokrynol Pol. 2007 Jul-Aug;58(4):322-9. Review.PMID: 18058724 [PubMed - indexed for MEDLINE]Related articles

An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy.

Annemans L, Demarteau N, Hu S, Lee TJ, Morad Z, Supaporn T, Yang WC, Palmer AJ.

Value Health. 2008 May-Jun;11(3):354-64. Epub 2007 Sep 21.PMID: 17888064 [PubMed - indexed for MEDLINE]Related articles

Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.

Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ.

Pharmacoeconomics. 2007;25(10):881-97.PMID: 17887808 [PubMed - indexed for MEDLINE]Related articles

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

Palmer AJ, Valentine WJ, Ray JA.

Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.PMID: 17877649 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of diabetes case management for low-income populations.

Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, Cobden D, Nicklasson L, Philis-Tsimikas A, Palmer AJ.

Health Serv Res. 2007 Oct;42(5):1943-59.PMID: 17850527 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-utility analysis of cinacalcet in addition to standard of care in the UK.

Ray JA, Valentine WJ, Palmer AJ.

Nephrol Dial Transplant. 2007 Nov;22(11):3355-7; author reply 3357-8. Epub 2007 Sep 4. No abstract available. PMID: 17785347 [PubMed - indexed for MEDLINE]Related articlesFree article

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.PMID: 17593245 [PubMed - indexed for MEDLINE]Related articles

Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.

Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ.

Adv Ther. 2007 Mar-Apr;24(2):273-90.PMID: 17565917 [PubMed - indexed for MEDLINE]Related articles

An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.

Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, Lammert M, Roze S.

Curr Med Res Opin. 2007 Apr;23(4):895-901.PMID: 17407646 [PubMed - indexed for MEDLINE]Related articles

Analysis of mouse skin reveals proteins that are altered in a diet-induced diabetic state: a new method for detection of type 2 diabetes.

List EO, Berryman DE, Palmer AJ, Qiu L, Sankaran S, Kohn DT, Kelder B, Okada S, Kopchick JJ.

Proteomics. 2007 Apr;7(7):1140-9.PMID: 17390296 [PubMed - indexed for MEDLINE]Related articles

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

Curr Med Res Opin. 2007 Mar;23(3):609-22.PMID: 17355742 [PubMed - indexed for MEDLINE]Related articles

Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.

Palmer AJ, Valentine WJ, Ray JA, Roze S, Muszbek N.

Eur J Health Econ. 2007 Jun;8(2):161-8. Epub 2007 Jan 20.PMID: 17237927 [PubMed - indexed for MEDLINE]Related articles

Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.

Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.

Diabetes Obes Metab. 2007 Jan;9(1):103-13.PMID: 17199725 [PubMed - indexed for MEDLINE]Related articles

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

Curr Med Res Opin. 2006 Nov;22(11):2095-100.PMID: 17076969 [PubMed - indexed for MEDLINE]Related articles

Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.

Palmer AJ, Currie CJ.

Pharmacoeconomics. 2006;24(9):927-9; author reply 929-35. No abstract available. PMID: 16942126 [PubMed - indexed for MEDLINE]Related articles

Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.

Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S.

Int J Clin Pract. 2006 Sep;60(9):1138-45. Review.PMID: 16939559 [PubMed - indexed for MEDLINE]Related articles

[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy]

Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H.

Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. German. PMID: 16868875 [PubMed - indexed for MEDLINE]Related articles

Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.

Roze S, Valentine WJ, Evers T, Palmer AJ.

Curr Med Res Opin. 2006 Jul;22(7):1415-24.PMID: 16834840 [PubMed - indexed for MEDLINE]Related articles

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.

Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brändle M.

Swiss Med Wkly. 2006 May 27;136(21-22):346-52.PMID: 16779715 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.

Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, Lurati FM, Roze S.

Adv Ther. 2006 Mar-Apr;23(2):191-207.PMID: 16751153 [PubMed - indexed for MEDLINE]Related articles

Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.

Currie CJ, McEwan P, Poole C, Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.

Curr Med Res Opin. 2006 May;22(5):967-9; author reply 968-9. No abstract available. PMID: 16709318 [PubMed - indexed for MEDLINE]Related articles

Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.

Palmer AJ, Dinneen S, Gavin JR 3rd, Gray A, Herman WH, Karter AJ.

Curr Med Res Opin. 2006 May;22(5):861-72.PMID: 16709308 [PubMed - indexed for MEDLINE]Related articles

Left ventricular hypertrophy determined by Sokolow-Lyon criteria: a different predictor in women than in men?

Antikainen RL, Grodzicki T, Palmer AJ, Beevers DG, Webster J, Bulpitt CJ; Department of Health and Social Security Hypertension Care Computer Project (DHCCP).

J Hum Hypertens. 2006 Jun;20(6):451-9.PMID: 16708082 [PubMed - indexed for MEDLINE]Related articles

Counting the costs of overweight and obesity: modeling clinical and cost outcomes.

Tucker DM, Palmer AJ, Valentine WJ, Roze S, Ray JA.

Curr Med Res Opin. 2006 Mar;22(3):575-86.PMID: 16574040 [PubMed - indexed for MEDLINE]Related articles

[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]

Frei A, Palmer AJ, Burnier M, Hess B.

Praxis (Bern 1994). 2006 Mar 15;95(11):401-8. German. PMID: 16570646 [PubMed - indexed for MEDLINE]Related articles

Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes.

Palmer AJ, Chen R, Valentine WJ, Roze S, Bregman B, Mehin N, Gabriel S.

Diabetes Metab. 2006 Feb;32(1):69-76.PMID: 16523189 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.

Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.

Curr Med Res Opin. 2005 Dec;21(12):2063-71.PMID: 16368057 [PubMed - indexed for MEDLINE]Related articles

Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.

Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, Palmer AJ.

Curr Med Res Opin. 2005 Oct;21(10):1617-29. Review.PMID: 16238902 [PubMed - indexed for MEDLINE]Related articles

Insulin pumps: more consultation was needed.

Palmer AJ, Tucker DM, Ray JA, Valentine WJ, Currie C, McEwan P, Brändle M.

BMJ. 2005 Oct 15;331(7521):905-6. No abstract available. PMID: 16223833 [PubMed - indexed for MEDLINE]Related articlesFree article

Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States.

Minshall ME, Roze S, Palmer AJ, Valentine WJ, Foos V, Ray J, Graham C.

Clin Ther. 2005 Jun;27(6):940-50.PMID: 16117994 [PubMed - indexed for MEDLINE]Related articles

Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.

Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ.

Diabet Med. 2005 Sep;22(9):1239-45.PMID: 16108855 [PubMed - indexed for MEDLINE]Related articles

A critical review of pharmacoeconomic studies of acamprosate.

Poldrugo F, Haeger DA, Comte S, Walburg J, Palmer AJ.

Alcohol Alcohol. 2005 Sep-Oct;40(5):422-30. Epub 2005 Jun 6.PMID: 15939706 [PubMed - indexed for MEDLINE]Related articlesFree article

Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries.

Palmer AJ, Valentine WJ, Roze S, Lammert M, Spiesser J, Gabriel S.

Curr Med Res Opin. 2005 Jan;21(1):19-26. Review.PMID: 15881472 [PubMed - indexed for MEDLINE]Related articles